Viking Therapeutics' Obesity Drug Trial Results Spark Market Interest
On September 22, Viking Therapeutics (VKTX) reported promising trial data for its experimental obesity drug VK2735. Patients who switched from weekly to monthly injections maintained an average of 85% of their prior weight loss, while those on every-other-week dosing preserved 90%. Participants continuing with weekly doses achieved a mean weight loss of 21.7%, showing no signs of plateau at week 33. The trial results highlight VK2735's potential to address adherence issues common in GLP-1 therapies, where many patients discontinue treatment within the first two years due to dosing frequency and maintenance requirements. Viking’s flexible dosing options could offer a more sustainable solution for long-term weight management. Shares of Viking Therapeutics surged 36% following the announcement, marking their largest single-day gain since February 2024. The results pose a potential challenge to market leaders Eli Lilly (LLY) and Novo Nordisk (NVO), as VK2735 employs a similar dual agonist mechanism used in their top-selling obesity drugs.
Topics: clinical trial results GLP-1 therapy obesity drugs stock movement